IPP Bureau
BioGenex RT-PCR Kit detects all Covid variants in half the time
By IPP Bureau - January 13, 2022
This test analyses samples in VTM directly without the need for RNA extraction step
AstraZeneca studies show its booster effective against all variants
By IPP Bureau - January 13, 2022
New data from ongoing trial showed increased antibody response against Beta, Delta, Alpha, Gamma and Omicron variants following third dose booster with Vaxzevria
AliveCor’ KardiaMobile gets NICE approval to detect irregular heart rhythm symptons
By IPP Bureau - January 13, 2022
KardiaMobile is the first personal ECG to be recommended by NICE for use within the National Health Service (NHS) in England and Wales
Merck KGaA appoints Global R&D Head & CSO for healthcare business sector
By IPP Bureau - January 13, 2022
Danny Bar-Zohar will become Global Head of R&D and Joern-Peter Halle will become Chief Strategy Officer
Veristat supported marketing applications for 12 % of all FDA Novel Drug Approvals in 2021
By IPP Bureau - January 12, 2022
This surpasses the number of approvals supported in 2020
Novel preventive vaccine for Parkinson’s move into human trials
By IPP Bureau - January 12, 2022
MultiTEP Platform-based vaccine targeting three B cell epitopes of pathological ?-Synuclein simultaneously shows protective efficacy in mouse model of synucleinopathies
Amgen and Arrakis collaborate for small molecule therapeutics
By IPP Bureau - January 12, 2022
Under the terms of the agreement, Arrakis will lead research activities for the identification of RNA-targeted small molecule (rSM) binders against a broad set of targets nominated by Amgen
Indian pharma industry registers 5.3% YoY revenue growth in Dec 2021 : Ind-Ra
By IPP Bureau - January 12, 2022
Ind-Ra expects revenue growth of over 12% in 2022.
Marksons Pharma receive final US. FDA approval for Cetirizine Hydrochloride tablets
By IPP Bureau - January 12, 2022
The product will be marketed under store brand labels and is comparable to the brand Zyrtec
Sinocompound and InCatT launch new Catalyst Screening Service
By IPP Bureau - January 12, 2022
This service benefits pharmaceutical and fine chemical companies looking to optimise their reactions
Alkem Labs to launch treatment for Diabetic Foot Ulcer
By IPP Bureau - January 12, 2022
This advanced technology for Diabetic Foot Ulcer (DFU), management has a high scope of preventing amputations in diabetic patients. It has no definitive treatment in India. This technology will be available at affordable rates
ABL Bio collaborates with SANOFI for Parkinson’s antibody
By IPP Bureau - January 12, 2022
ABL and SANOFI to collaborate on the development of ABL301, a potential first-in-class bispecific antibody targeting alpha-synuclein and containing a proprietary brain shuttle, for alpha-synucleinopathies, including Parkinson's disease
Covaxin booster neutralises Omicron and Delta variants: Study
By IPP Bureau - January 12, 2022
The study will be published on the pre-print server, medRXiv, shortly
Wacker and Biosyntia to develop production process for sustainable biotin
By IPP Bureau - January 11, 2022
The long-term partnership aims to make fermentation-based biotin available for the full range of relevant applications as a sustainable, non-chemical, European-sourced alternative
Merck’s KEYTRUDA shows promise as adjuvant treatment for non-small cell lung cancer
By IPP Bureau - January 11, 2022
First Positive Study for KEYTRUDA in Adjuvant Stage IB-IIIA NSCLC
